If approved, the new indication would make frontline Avastin available in combination with carboplatin and paclitaxel, followed by Avastin alone, for women with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. The FDA is expected to render a decision on the sBLA by June 25, 2018.
What happens when the hustle, bustle, attention and care of active treatment end? Survivor shares what helped.
A cancer survivor weighs his losses and gains.
While the use of Jakafi (ruxolitinib) is firmly rooted in the treatment paradigm for patients with myelofibrosis, other novel agents, such as momelotinib and pacritinib are also gaining the interest of researchers in the field.
Chemotherapy-induced nausea and vomiting (CINV) is a common — and often costly — problem among patients with cancer.
Did a miracle occur after Mary Jane passed away from ovarian cancer?
Two-time cancer survivor talks about managing fatigue.
A free two-day workshop will train people who want to raise awareness of liver diseases and influence public health policy to address their concerns.
A new agent will soon be available to treat chemotherapy-induced nausea and vomiting.
Cancer weight is the pits!
Cancer survivor comments on life in an emptying nest.
Scientists in the lab and in the clinic can help patients with metastatic breast cancer make informed choices.
Once weekly Kyprolis (carfilzomib) had better efficacy than lower-doses of the drug given twice a week to treat patients with relapsed/refractory multiple myeloma, according to results from the phase 3 ARROW trial.
Consistently living in the past with a cancer diagnosis will never let you just enjoy the life of the present.
Shared breathing can help support and promote the sensual experience for survivors of cancer.
